Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Wietske Kievit; Noortje van Herwaarden; Frank H. J. van den Hoogen; Ronald F. van Vollenhoven; Johannes W. J. Bijlsma; Bart J. F. van den Bemt; Aatke van der Maas; Alfons A. den Broeder

doi:10.1136/annrheumdis-2015-208317

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Wietske Kievit^*, Noortje van Herwaarden, Frank H. J. van den Hoogen, Ronald F. van Vollenhoven, Johannes W. J. Bijlsma, Bart J. F. van den Bemt, Aatke van der Maas, Alfons A. den Broeder

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1939-1944
Journal	Annals of the Rheumatic Diseases
Volume	75
Issue number	11
DOIs	https://doi.org/10.1136/annrheumdis-2015-208317
Publication status	Published - Nov 2016

Access to Document

10.1136/annrheumdis-2015-208317

Cite this

Kievit, W., van Herwaarden, N., van den Hoogen, F. H. J., van Vollenhoven, R. F., Bijlsma, J. W. J., van den Bemt, B. J. F., van der Maas, A., & den Broeder, A. A. (2016). Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases, 75(11), 1939-1944. https://doi.org/10.1136/annrheumdis-2015-208317

Kievit, Wietske ; van Herwaarden, Noortje ; van den Hoogen, Frank H. J. ; van Vollenhoven, Ronald F. ; Bijlsma, Johannes W. J. ; van den Bemt, Bart J. F. ; van der Maas, Aatke ; den Broeder, Alfons A. / Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. In: Annals of the Rheumatic Diseases. 2016 ; Vol. 75, No. 11. pp. 1939-1944.

@article{5a8a03d1f3ed411d8cfa3cb7b5bd2771,

title = "Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study",

author = "Wietske Kievit and {van Herwaarden}, Noortje and {van den Hoogen}, {Frank H. J.} and {van Vollenhoven}, {Ronald F.} and Bijlsma, {Johannes W. J.} and {van den Bemt}, {Bart J. F.} and {van der Maas}, Aatke and {den Broeder}, {Alfons A.}",

year = "2016",

month = nov,

doi = "10.1136/annrheumdis-2015-208317",

language = "English",

volume = "75",

pages = "1939--1944",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "11",

}

Kievit, W, van Herwaarden, N, van den Hoogen, FHJ, van Vollenhoven, RF, Bijlsma, JWJ, van den Bemt, BJF, van der Maas, A & den Broeder, AA 2016, 'Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study', Annals of the Rheumatic Diseases, vol. 75, no. 11, pp. 1939-1944. https://doi.org/10.1136/annrheumdis-2015-208317

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. / Kievit, Wietske; van Herwaarden, Noortje; van den Hoogen, Frank H. J.; van Vollenhoven, Ronald F.; Bijlsma, Johannes W. J.; van den Bemt, Bart J. F.; van der Maas, Aatke; den Broeder, Alfons A.

In: Annals of the Rheumatic Diseases, Vol. 75, No. 11, 11.2016, p. 1939-1944.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

AU - Kievit, Wietske

AU - van Herwaarden, Noortje

AU - van den Hoogen, Frank H. J.

AU - van Vollenhoven, Ronald F.

AU - Bijlsma, Johannes W. J.

AU - van den Bemt, Bart J. F.

AU - van der Maas, Aatke

AU - den Broeder, Alfons A.

PY - 2016/11

Y1 - 2016/11

U2 - 10.1136/annrheumdis-2015-208317

DO - 10.1136/annrheumdis-2015-208317

M3 - Article

C2 - 26764260

VL - 75

SP - 1939

EP - 1944

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 11

ER -

Kievit W, van Herwaarden N, van den Hoogen FHJ, van Vollenhoven RF, Bijlsma JWJ, van den Bemt BJF et al. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases. 2016 Nov;75(11):1939-1944. https://doi.org/10.1136/annrheumdis-2015-208317